| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053088926 |
| P356 | DOI | 10.1054/BJOC.2000.1689 |
| P932 | PMC publication ID | 2363818 |
| P698 | PubMed publication ID | 11259094 |
| P5875 | ResearchGate publication ID | 12073738 |
| P50 | author | Chris J L M Meijer | Q90379336 |
| P2093 | author name string | Helmerhorst TJ | |
| van den Brule AJ | |||
| Rozendaal L | |||
| Verheijen RH | |||
| Risse EK | |||
| Nobbenhuis MA | |||
| Voorhorst FJ | |||
| P2860 | cites work | A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix | Q31987917 |
| Results of conservative management of cervical intraepithelial neoplasia | Q33271805 | ||
| Large loop excision of the transformation zone (LLETZ) compared to carbon dioxide laser in the treatment of CIN: a superior mode of treatment | Q34243314 | ||
| A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings | Q36543787 | ||
| Healing of cervical epithelium after laser treatment of cervical intraepithelial neoplasia | Q36627076 | ||
| Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia | Q36763299 | ||
| Human papillomavirus types and recurrent cervical warts | Q43572901 | ||
| Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens | Q44830999 | ||
| Natural history of cervicovaginal papillomavirus infection in young women. | Q50909200 | ||
| Genital papillomavirus infection after treatment for cervical intraepithelial neoplasia (CIN) III | Q69838272 | ||
| Efficacy and safety of large-loop excision of the transformation zone | Q72665558 | ||
| A study of the follow up patterns of women treated for CIN 2 and 3 before and after the introduction of the 1992 guidelines | Q73152877 | ||
| Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri | Q73538537 | ||
| Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology | Q74447110 | ||
| Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study | Q78001750 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervical intraepithelial neoplasia | Q196788 |
| P304 | page(s) | 796-801 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia | |
| P478 | volume | 84 |
| Q46837519 | A comparison of human papillomavirus testing of clinician‐collected and self‐collected samples during follow‐up after screen‐and‐treat |
| Q35769502 | Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. |
| Q92131918 | CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology |
| Q36109812 | Clinical relevance of human papillomavirus testing in cytopathology. |
| Q81195427 | Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence |
| Q33885141 | Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia |
| Q51600095 | Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. |
| Q34102517 | Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? |
| Q36423738 | Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma |
| Q47721285 | Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization |
| Q36739942 | Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management |
| Q40500436 | Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable |
| Q24186721 | Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test |
| Q51644487 | HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. |
| Q79124299 | HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3 |
| Q26771420 | HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions |
| Q54447229 | HPV16 and increased risk of recurrence after treatment for CIN. |
| Q40861801 | High risk HPV testing following treatment for cervical intraepithelial neoplasia |
| Q54377755 | High risk human papillomavirus genotyping in clinical samples: evaluation of different commercial tests. |
| Q34135249 | High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis |
| Q37570873 | History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results |
| Q84147482 | How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands |
| Q34580052 | Human papillomavirus and cervical cancer |
| Q41446278 | Human papillomavirus genotype distribution among Cameroonian women with invasive cervical cancer: a retrospective study. |
| Q34514132 | Human papillomavirus in cervical cancer |
| Q37266480 | Human papillomavirus testing for primary cervical cancer screening |
| Q36608673 | Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. |
| Q46584014 | Markers of HPV infection and survival in patients with head and neck tumors. |
| Q30573204 | Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada |
| Q79159044 | Moderate variation of the oncogenic potential among high‐risk human papillomavirus types in gynecologic patients with cervical abnormalities |
| Q49031839 | Natural history and clearance of HPV after treatment of precancerous cervical lesions |
| Q33318598 | PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia |
| Q30238779 | Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review |
| Q37376872 | Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review |
| Q35805474 | Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis. |
| Q57279421 | Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2–3 |
| Q85092805 | Predictors of recurrence in high-grade cervical lesions and a plan of management |
| Q34400805 | Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya |
| Q35037359 | Risk factors related to the development and mortality from invasive cervical cancer clinical utility and impact on prevention |
| Q51036686 | Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. |
| Q35006179 | Role of HPV testing in clinical practice |
| Q37248554 | Role of high risk-human papilloma virus test in the follow-up of patients who underwent conization of the cervix for cervical intraepithelial neoplasia |
| Q41489942 | Role of human papillomavirus testing and cytology in follow-up after conization |
| Q36974667 | The Association of High Risk Human Papillomaviruses in Patients With Cervical Cancer: An Evidence Based Study on Patients With Squamous Cell Dysplasia or Carcinoma for Evaluation of 23 Human Papilloma Virus Genotypes |
| Q24673148 | The causal relation between human papillomavirus and cervical cancer |
| Q35984769 | The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review |
| Q44590365 | The role of HPV DNA testing in the follow-up of cervical intraepithelial neoplasia after loop electrosurgical excision procedure. |
| Q33560999 | The utility of the human papillomavirus DNA load for the diagnosis and prediction of persistent vaginal intraepithelial neoplasia |
| Q54402491 | Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. |
| Q41715686 | Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix. |
Search more.